Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
Condition(s):Peripheral T-cell Lymphomas (PTCL)Last Updated:November 3, 2021Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Peripheral T-cell Lymphomas (PTCL)Last Updated:November 3, 2021Not yet recruiting
Condition(s):Newly Diagnosed Multiple MyelomaLast Updated:September 28, 2022Not yet recruiting
Condition(s):Multiple MyelomaLast Updated:July 26, 2013Completed
Condition(s):Diffuse Large B Cell Lymphoma Relapsed; Diffuse Large B Cell Lymphoma RefractoryLast Updated:February 5, 2019Completed
Condition(s):Relapsed or Refractory Systemic Light Chain AmyloidosisLast Updated:September 21, 2023Terminated
Condition(s):Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:February 4, 2022Completed
Condition(s):Antibiotics-unresponsive MALT Lymphoma; Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma; Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)Last Updated:October 27, 2020Unknown status
Condition(s):Central Nervous System LymphomaLast Updated:March 2, 2022Recruiting
Condition(s):Diffuse Large B Cell LymphomaLast Updated:June 16, 2020Recruiting
Condition(s):Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)Last Updated:September 30, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.